Prognosis of cholangiocarcinoma patients based on multiple patterns of programmed cell death, integrated analysis of the immune microenvironment and drug sensitivity

Prognosis of cholangiocarcinoma patients based on multiple patterns of programmed cell death, integrated analysis of the immune microenvironment and drug sensitivity

BackgroundCholangiocarcinoma (CHOL) is a highly malignant bile duct cancer with a poor prognosis and rising incidence. Programmed cell death (PCD) plays a crucial role in cancer biology, influencing tumor immunity and treatment response. This study analyzes the impact of multiple PCD patterns on CHO...

Full description

Saved in:
Bibliographic Details
Main Authors: Yupeng Xu, Jian Sun, Xin Yan, Zhenliao Mao, Yiming Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Genetics
Subjects:
cholangiocarcinoma
programmed cell death
prognostic model
tumor microenvironment
RNA-seq
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2025.1457204/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundCholangiocarcinoma (CHOL) is a highly malignant bile duct cancer with a poor prognosis and rising incidence. Programmed cell death (PCD) plays a crucial role in cancer biology, influencing tumor immunity and treatment response. This study analyzes the impact of multiple PCD patterns on CHOL prognosis, tumor microenvironment (TME) and drug sensitivity.MethodsRNA sequencing data from TCGA-CHOL and GSE107943 were analyzed to identify PCD-related genes. A PCD-associated Risk Score was constructed using Cox and Lasso regression analyses. The score’s prognostic value was assessed through survival analysis, ROC curves, and functional annotation.ResultsWe identified 111 differentially expressed PCD-related genes, including NCK2, BNIP3 and BIK, that constituted PCD-associated Risk Score and correlated with prognosis of CHOL. Functional analyses indicated enrichment in immune-related processes. High-risk patients showed increased immune cell infiltration and higher immune checkpoint expression, suggesting a benefit from immunotherapy. They also demonstrated greater sensitivity to several chemotherapeutic and targeted agents.ConclusionPCD-associated Risk Score is a robust prognostic tool for CHOL, influencing TME modulation and therapeutic response, and may guide personalized treatment strategies.
ISSN:1664-8021

Similar Items